Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases

The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group). The primary outcome measures will be clinical improvement based on the respective disease specific clinical scores, normalization of T-lymphocyte subsets and \> 50% reduction in disease specific antibody titres. The study will also document the type and frequency of any adverse event or side effects, reported by or seen in any of the trial participants. Patients in treatment group will receive single session of MSC therapy and placebo group will receive 0.9% saline solution. The participants will be followed at 3 and 6 months.

NCT Number	NCT06888973
Lead Sponsor	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan Collaborators: Pak Emirates Military Hospital
Conditions	Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Ankylosing Spondylitis (AS), Juvenile Idiopathic Arthritis, Polymyositis/Dermatomyositis
Enrollment	200 participants
Start Date	2025-02-01
Primary Completion	2025-02-01 (estimated)
Study Completion	2026-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-21